130 related articles for article (PubMed ID: 36712425)
1. hPG
Casile M; Passildas J; Vire B; Molnar I; Durando X
Front Neurol; 2022; 13():1073476. PubMed ID: 36712425
[TBL] [Abstract][Full Text] [Related]
2. hPG
Chauhan A; Prieur A; Kolesar J; Arnold S; Payen L; Mahi Y; Vire B; Sands M; Evers BM; Joubert D; Anthony L
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205614
[TBL] [Abstract][Full Text] [Related]
3. Plasma hPG
Prieur A; Harper A; Khan M; Vire B; Joubert D; Payen L; Kopciuk K
BMC Cancer; 2023 Apr; 23(1):305. PubMed ID: 37016331
[TBL] [Abstract][Full Text] [Related]
4. The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients.
You B; Mercier F; Assenat E; Langlois-Jacques C; Glehen O; Soulé J; Payen L; Kepenekian V; Dupuy M; Belouin F; Morency E; Saywell V; Flacelière M; Elies P; Liaud P; Mazard T; Maucort-Boulch D; Tan W; Vire B; Villeneuve L; Ychou M; Kohli M; Joubert D; Prieur A
EBioMedicine; 2020 Jan; 51():102574. PubMed ID: 31877416
[TBL] [Abstract][Full Text] [Related]
5. Plasma hPG
Dupuy M; Iltache S; Rivière B; Prieur A; Pageaux GP; Bedoya JU; Faure S; Guillaumée H; Assenat E
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053564
[TBL] [Abstract][Full Text] [Related]
6. Association between post-operative hPG
Doucet L; Cailleteau A; Vaugier L; Gourmelon C; Bureau M; Salaud C; Roualdes V; Samarut E; Aumont M; Zenatri M; Loussouarn D; Quillien V; Bocquet F; Payen-Gay L; Joubert D; Prieur A; Robert M; Frenel JS
ESMO Open; 2023 Oct; 8(5):101626. PubMed ID: 37713930
[TBL] [Abstract][Full Text] [Related]
7. [hPG
You B; Assenat E; Payen L; Mazard T; Glehen O; Calattini S; Villeneuve L; Lescuyer G; Vire B; Ychou M
Bull Cancer; 2022 Jun; 109(6):707-713. PubMed ID: 35597620
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Plasma hPG
Kohli M; Tan W; Vire B; Liaud P; Blairvacq M; Berthier F; Rouison D; Garnier G; Payen L; Cousin T; Joubert D; Prieur A
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498444
[TBL] [Abstract][Full Text] [Related]
9. A novel method to detect hPG
Cappellini M; Flaceliere M; Saywell V; Soule J; Blanc E; Belouin F; Ortiz E; Canterel-Thouennon L; Poupeau S; Tigrett S; Vire B; Liaud P; Blairvacq M; Joubert D; Prieur A
Anal Methods; 2021 Oct; 13(38):4468-4477. PubMed ID: 34494619
[TBL] [Abstract][Full Text] [Related]
10. Progastrin: An Overview of Its Crucial Role in the Tumorigenesis of Gastrointestinal Cancers.
Fioretzaki R; Sarantis P; Charalampakis N; Christofidis K; Mylonakis A; Koustas E; Karamouzis MV; Sakellariou S; Schizas D
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672239
[TBL] [Abstract][Full Text] [Related]
11. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.
Battersby NJ; Dattani M; Rao S; Cunningham D; Tait D; Adams R; Moran BJ; Khakoo S; Tekkis P; Rasheed S; Mirnezami A; Quirke P; West NP; Nagtegaal I; Chong I; Sadanandam A; Valeri N; Thomas K; Frost M; Brown G
Trials; 2017 Aug; 18(1):394. PubMed ID: 28851403
[TBL] [Abstract][Full Text] [Related]
12. Progastrin and cyclooxygenase-2 in colorectal cancer.
Konturek PC; Bielanski W; Konturek SJ; Hartwich A; Pierzchalski P; Gonciarz M; Marlicz K; Starzynska T; Zuchowicz M; Darasz Z; Götze JP; Rehfeld JF; Hahn EG
Dig Dis Sci; 2002 Sep; 47(9):1984-91. PubMed ID: 12353842
[TBL] [Abstract][Full Text] [Related]
13. INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer.
Veyssière H; Lusho S; Molnar I; Kossai M; Bernadach M; Abrial C; Bidet Y; Radosevic-Robin N; Durando X
Front Oncol; 2021; 11():653370. PubMed ID: 34249690
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of progastrin but not amidated gastrin or glycine extended gastrin are elevated in patients with colorectal carcinoma.
Siddheshwar RK; Gray JC; Kelly SB
Gut; 2001 Jan; 48(1):47-52. PubMed ID: 11115822
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Kitchener HC; Nijman HW; Kruitwagen RF; Nout RA; Verhoeven-Adema KW; Smit VT; Putter H; Creutzberg CL;
Lancet Oncol; 2016 Aug; 17(8):1114-1126. PubMed ID: 27397040
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
[TBL] [Abstract][Full Text] [Related]
17. "Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors".
Gernier F; Ahmed-Lecheheb D; Pautier P; Floquet A; Nadeau C; Frank S; Alexandre J; Selle F; Berton-Rigaud D; Kalbacher E; Orfeuvre H; Lortholary A; Augereau P; Labombarda F; Perrier L; Grellard JM; Licaj I; Clarisse B; Savoye AM; Bourien H; De La Motte Rouge T; Kurtz JE; Kerdja K; Lelaidier A; Charreton A; Ray-Coquard I; Joly F
BMC Cancer; 2021 Oct; 21(1):1147. PubMed ID: 34702204
[TBL] [Abstract][Full Text] [Related]
18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
19. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
20. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
